10x Genomics Inc - Class A

TXG

$41.25

+30.3% last 12 months

Baillie Gifford Holding value: $351 Million Sands Capital Holding value: $170 Million Cathie Wood Holding value: $128 Million Al Gore Holding value: $83.1 Million Steven Cohen Holding value: $66.1 Million Ken Griffin Holding value: $29.8 Million Ron Baron Holding value: $1.14 Million Joel Greenblatt Holding value: $285 Thousand Andreas Halvorsen Holding value: $0 PRIMECAP Management Holding value: $0 Jim Simons Holding value: $0 Ray Dalio Holding value: $0 Daniel Loeb Holding value: $0 Stanley Druckenmiller Holding value: $0

Market Cap

$4.26 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$23.81 - $63.57

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

-24.75x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $4.26 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $3.87 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. +30.3%
52-Week High Highest share price in the last 52 weeks. $63.57
52-Week Low Lowest share price in the last 52 weeks. $23.81
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 2.1
Outstanding Shares The number of shares the company has issued and are held by stockholders. 103 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 963 Thousand

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. -24.75
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 780.4
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. -$1.49
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 8.25
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 5.89
Enterprise Value to Revenue Enterprise value divided by revenue 6.81
Enterprise Value to EBIT Enterprise Value divided by EBIT -21.7
Total Debt to Enterprise Value Total debt divided by enterprise value 0.0
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.0

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $568 Million
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $418 Million
EBIT Earnings before tax and interest payments. -$178 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. -$172 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -30.31%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -3.2%
Return on Equity Equity divided by market cap. -21.72%
Return on Assets Indicates a company's profitability in relation to its total assets. -17.41%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. -20.01%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q1 2023 Q2 2023 Q3 2023 Q4 2023

About 10x Genomics Inc - Class A

CEO: Serge Saxonov

Industry: Testing Laboratories

Similar stocks

NovoCure Ltd
NovoCure Ltd
Novavax, Inc.
Novavax, Inc.
Organovo Holdings Inc
Organovo Holdings Inc
Orchard Therapeutics plc - ADR
Orchard Therapeutics plc - ADR

News

NanoString falls amid report of prelim injunction in Germany in dispute with 10x Genomics

NanoString falls amid report of prelim injunction in Germany in dispute with 10x Genomics

NanoString Technologies (NSTG) fell 10% on a report that a German court announced a preliminary injunction against it over a patent dispute with 10X Genomics...

Seeking Alpha Seeking Alpha, 14 days ago
10x Genomics Expands Gene Expression Flex Offering with Latest High-Throughput Multiomic Profiling Kit

10x Genomics Expands Gene Expression Flex Offering with Latest High-Throughput Multiomic Profiling Kit

Strengthen cellular evaluation with cost-efficient multiomic readouts and streamlined workflows PLEASANTON, Calif., Sept. 14, 2023 /PRNewswire/ — 10x Genomic...

TodaysStocks.com TodaysStocks.com, 18 days ago
Psomagen Puts Spatial Biology and Multiomics in Focus, first CRO to launch 10X Genomics Xenium™ in situ Analyzer services in North America

Psomagen Puts Spatial Biology and Multiomics in Focus, first CRO to launch 10X Genomics Xenium™ in situ Analyzer services in North America

Kwhen Finance Kwhen Finance, 20 days ago
Barclays Increases 10x Genomics (NASDAQ:TXG) Price Target to $66.00

Barclays Increases 10x Genomics (NASDAQ:TXG) Price Target to $66.00

10x Genomics (NASDAQ:TXG – Get Free Report) had its price objective hoisted by research analysts at Barclays from $65.00 to $66.00 in a note issued to invest...

The AM Reporter The AM Reporter, about 2 months ago
Never miss a trade
To improve your user experience we use cookies.